Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Journal of Hepatology

Volumn 67, Issue 2, 2017, Pages 263-271

  Kwo, Paul Y ^a   Poordad, Fred ^b   Asatryan, Armen ^c   Wang, Stanley ^c   Wyles, David L ^d   Hassanein, Tarek ^e   Felizarta, Franco ^f   Sulkowski, Mark S ^g   Gane, Edward ^h   Maliakkal, Benedict ⁱ   Overcash, J Scott ^j   Gordon, Stuart C ^k   Muir, Andrew J ^l   Aguilar, Humberto ^m   Agarwal, Kosh ⁿ   Dore, Gregory J ^o   Lin, Chih Wei ^c   Liu, Ran ^c   Lovell, Sandra S ^c   Ng, Teresa I ^c   Kort, Jens ^c   Mensa, Federico J ^c   more..

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c ABBVIE INC   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e Southern California Liver Centers and Southern California Research Center   (United States)

^f Private Practice   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF AUCKLAND   (New Zealand)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^j ECMC Department of Surgery   (United States)

^k HENRY FORD HEALTH SYSTEM   (United States)

^l DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m Louisiana Blood Center   (United States)

ⁿ KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^o ST VINCENT S HOSPITAL   (Australia)

more..

Author keywords

ABT 493; ABT 530; D alanine transaminase; Direct acting antiviral; Genotype; Hepatitis C, chronic; Interferons; Liver cirrhosis; Pangenotypic; SURVEYOR; Sustained virologic response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLECAPREVIR; HEMOGLOBIN; PIBRENTASVIR; RIBAVIRIN; ABT-493; ABT-530; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENETIC POLYMORPHISM; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HYPERTRANSAMINASEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHRONIC HEPATITIS C; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; MULTIDRUG RESISTANCE; PHASE 2 CLINICAL TRIAL; TREATMENT FAILURE; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PYRROLIDINES; QUINOXALINES; RIBAVIRIN; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE;

EID: 85019575184     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.03.039     Document Type: Article

References (22)

1. Razavi, H., Waked, I., Sarrazin, C., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepatitis 21 (2014), 34–59.
2. Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
3. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61 (2014), S45–S57.
4. Ampuero, J., Romero-Gomez, M., Reddy, K.R., Review article: HCV genotype 3 - the new treatment challenge. Aliment Pharmacol Ther 39 (2014), 686–698.
5. Sciences, G., EPCLUSA (sofosbuvir and velpatasvir) [package insert]. 2016, Foster City, CA.
6. Asselah, T., Boyer, N., Saadoun, D., Martinot-Peignoux, M., Marcellin, P., Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 36 (2016), 47–57.
7. Pawlotsky, J.M., New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146 (2014), 1176–1192.
8. Zeuzem, S., Ghalib, R., Reddy, K.R., et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med, 2015, 10.7326/M7315-0785.
9. Younossi, Z.M., Kanwal, F., Saab, S., et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 39 (2014), 518–531.
10. Lawitz, E.J., O'Riordan, W.D., Asatryan, A., et al. Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection. Antimicrob Agents Chemother 60 (2015), 1546–1555.
11. Ng, T., Krishnan, P., Pilot-Matias, T., et al. In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother, 2017.
12. Gane, E., Poordad, F., Wang, S., et al. High efficacy of ABT-493 and ABT-530 in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology, 2016.
13. Lawitz, E.J., O'Riordan, W.D., Asatryan, A., et al. Potent antiviral activity of direct-acting antivirals, ABT-493 and ABT-530, with 3-day monotherapy for hepatitis C genotype 1 infection. Antimicrob Agents Chemother, 2015.
14. Wang, C., Jia, L., O'Boyle, D.R. 2nd, et al. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother 58 (2014), 5155–5163.
15. OLYSIO (simeprevir) [package insert]. Janssen Therapeutics. Titusville, NJ2013.
16. Cheng, G., Tian, Y., Doehle, B., et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother 60 (2016), 1847–1853.
17. Hernandez, D., Zhou, N., Ueland, J., Monikowski, A., McPhee, F., Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 57 (2013), 13–18.
18. Liu, R., Curry, S., McMonagle, P., et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother 59 (2015), 6922–6929.
19. Administration FaD. Division of Antiviral Products Virology Review, NDA 208341. 2015.
20. Krishnan, P., Beyer, J., Mistry, N., et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of HCV NS5A. Antimicrob Agents Chemother, 2014.
21. Muir, A.J., Strasser, S., Wang, S., Shafran, S., Bonacini, M., Kwo, P., et al. High SVRRates with ABT-493 + ABT-530 co-administered for 8 weeks in non-cirrhotic patients with HCV genotype 3 infection. Hepatology 64 (2016), 183–212.
22. Hassanein T, Wyles, D., Wang, S. et al. Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration: SURVEYOR-II, Part 4.). Paper presented at: The Liver Meeting 2016; Boston, MA.